Development of FUB 181, a selective histamine H3-receptor antagonist of high oral in vivo potency with 4-(ω-(arylalkyloxy)alkyl)-1H-imidazole structure

Archiv der Pharmazie

Volumn 331, Issue 6, 1998, Pages 211-218

  Stark, Holger ^a   Hüls, Annette ^a   Ligneau, Xavier ^b   Purand, Katja ^a   Pertz, Heinz ^a   Arrang, Jean Michel ^c   Schwartz, Jean Charles ^c   Schunack, Walter ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Laboratoire Bioprojet   (France)

^c CENTRE PAUL BROCA   (France)

Author keywords

Antagonist; FUB 181; Histamine H3 receptor; Imidazolylpropyl ether

Indexed keywords

4 [3 [3 (4 FLUOROPHENYL)PROPYLOXY]PROPYL] 1H IMIDAZOLE; ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; ETHER DERIVATIVE; FUB 181; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; MUSCARINIC M3 RECEPTOR; N METHYLHISTAMINE; SEROTONIN 2A RECEPTOR; SEROTONIN 3 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ALKANES; ANIMALS; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; HISTAMINE ANTAGONISTS; IMIDAZOLES; METHYLHISTAMINES; MICE; RATS; RECEPTOR, MUSCARINIC M3; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, HISTAMINE H3; RECEPTORS, MUSCARINIC; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTOSOMES;

EID: 2642708346     PISSN: 03656233     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-4184(199806)331:6<211::AID-ARDP211>3.0.CO;2-P     Document Type: Article

References (52)

1. J.C. Schwartz, J.-M. Arrang, M. Garbarg, J.-M. Lecomte, C. R. Ganellin, A. Fkyerat, W. Tertiuk, W. Schunack, R. Lipp, H. Stark, K. Purand, PCT Int. Appl. WO 93/14070, 1992 [Chem. Abstr. 1994 120, 107004c].
2. J.-M. Arrang, M. Garbarg, J.-C. Lancelot, J.-M. Lecomte, M. F. Robba, J.-C. Schwartz, Eur. Pat. Appl. EP 494 010, 1990.
3. C. R. Ganellin, S. K. Hosseini, Y. S. Khalaf, W. Tertiuk, J.-M. Arrang, M. Garbarg, X. Ligneau, J.-C. Schwartz, J. Med. Chem. 1995, 38, 3342-3350.
4. H. Van der Goot, M. J. P. Schepers, G. J. Sterk, H. Timmerman, Eur. J. Med. Chem. 1992, 27, 511-517.
5. G. J. Durant, A. M. Khan, Patent PCT WO 93/20061, 1993.
6. J.-M. Arrang, M. Garbarg, J.-C. Schwartz, Nature (London) 1983, 302, 832-837.
7. E. Schlicker, B. Malinowska, M. Kathmann, M. Göthert, Fundam. Clin. Pharmacol. 1994, 8, 128-137.
8. G. Coruzzi, G. Bertaccini, J.-C. Schwartz, Naunyn-Schmiedeberg's Arch. Pharmacol. 1991, 343, 225-227.
9. M. Ichinose, C. D. Stretton, J.-C. Schwartz, P. J. Barnes, Br. J. Pharmacol. 1989, 97, 13-15.
10. M. Imamura, N. Seyedi, H. M. Lander, R. Levi, Circ. Res. 1995, 77, 206-210.
11. K. Fink, E. Schlicker, M. Göthert, Adv. Biosci. 1991, 82, 125-126.
12. E. Schlicker, K. Fink, M. Detzner, M. Göthert, J. Neural. Transm. [Gen.Sect] 1993, 93, 1-10.
13. J. Clapham, G. J. Kilpatrick, Br. J. Pharmacol. 1992, 107, 919-923.
14. E. Schlicker, R. Betz, M. Göthert, Naunyn-Schmiedeberg's Arch. Pharmacol. 1988, 337, 588-590.
15. J. L. Burgaud, N. Oudart, J. Pharm. Pharmacol. 1993, 45, 955-958.
16. A. Bado, L. Moizo, J. P. Laigneau, M. J. M. Lewin, Am. J. Physiol. 1992, 262, G56-61.
17. H. Stark, E. Schlicker, W. Schunack, Drugs Future 1996, 21, 507-520.
18. R. Lipp, H. Stark, W. Schunack in The Histamine Receptor, Receptor Biochemistry and Methodology (Eds.: J.-C. Schwartz, H. L. Haas) Wiley-Liss, Inc.: New York, 1992; 16, pp 57-72.
19. R. Leurs, R. C. Vollinga, H. Timmerman, Prog. Drug Res. 1995, 45, 107-165.
20. C. E. Tedfort, S. L. Yates, G. P. Pawlowski, J. W. Nalwalk, L. B. Hough, M. A. Khan, J. G. Phillips, G. J. Durant, R. C. A. Frederickson, J. Pharmacol. Exp. Ther. 1995, 275, 589-604.
21. K. I. Meguro, K. Yanai, N. Sakai, E. Sakurai, K. Maeyama, H. Sasaki, T. Watanabe, Pharmacol. Biochem. Behav. 1995, 50, 321-525.
22. J. M. Monti, Life Sci. 1993, 53, 1331-1338.
23. H. Yokoyama, K. Onodera, K. Iinuma, T. Watanabe, Eur. J. Pharmacol. 1993, 234, 129-133.
24. J.M. Arrang, M. Garbarg, T. T. Quach, M. D. Trung Tuong, E. Yeramian, J.-C. Schwartz, Eur. J. Pharmacol. 1985, 111, 73-84.
25. J.-C. Schwartz, J.-M. Arrang, M. Garbarg, H. Pollard, Agents Actions 1990, 30, 13-23.
26. M. Kathmann, E. Schlicker, M. Göthert, Psychopharmacol. 1994, 116, 464-468.
27. K. Kiec-Kononowicz, X. Ligneau, H. Stark, J.-C. Schwartz, W. Schunack, Arch. Pharm. (Weinheim) 1995, 328, 445-450.
28. K. Kiec-Kononowics, X. Ligneau, J.-C. Schwartz, W. Schunack, Arch. Pharm. Pharm. Med. Chem. 1995, 328, 469-472.
29. H. Stark, R. Lipp, J.-M. Arrang, M. Garbarg, X. Ligneau, J.-C. Schwartz, W. Schunack, Eur. J. Pharm. Sci. 1995, 3, 95-104.
30. C. R. Ganellin, B. Bang-Andersen, Y. S. Khalaf, W. Tertiuk, J.-M. Arrang, M. Garbarg, X. Ligneau, A. Rouleau, J.-C. Schwartz, Bioorg. Med. Chem. Lett. 1992, 2, 1231-1234.
31. H. Stark, M. Krause, J.-M. Arrang, X. Ligneau, J.-C. Schwartz, W. Schunack, Bioorg. Med. Chem. Lett. 1994, 4, 2907-2912.
32. H. Stark, K. Purand, A. Hüls, X. Ligneau, M. Garbarg, J.-C. Schwartz, W. Schunack, J. Med. Chem. 1996, 39, 1220-1226.
33. K. Purand, H. Stark, X. Ligneau, M. Garbarg, J.-C. Schwartz, W. Schunack, Eur. J. Pharm. Sci. 1994, 2, 140.
34. E. Schlicker, M. Kathmann, H. Bitschnau, I. Marr, S. Reidemeister, H. Stark, W. Schunack, Naunyn-Schmiedeberg's Arch. Pharmacol. 1996, 353, 482-488.
35. R. Leurs, M. T. M. Tulp, W. B. P. Menge, M. J. P. Adolfs, O. P. Zuiderveld, H. Timmerman, Br. J. Pharmacol. 1995, 116, 2315-2321.
36. A. Hüls, K. Purand, H. Stark, S. Reidemeister, X. Ligneau, J.-M. Arrang, J.-C. Schwartz, W. Schunack, Arch. Pharm. Pharm. Med. Chem. 1996, 329, 379-385.
37. M. Garbarg, J.-M. Arrang, A. Rouleau, X. Ligneau, M. Dam Trung Tuong, J.-C. Schwartz, C. R. Ganellin, J. Pharmacol. Exp. Ther. 1992, 263, 304-310.
38. H. Pertz, S. Elz, J. Pharm. Pharmacol. 1995, 47, 310-316.
39. H. Meerwein in Methoden der organischen Chemie (Houben-Weyl): Georg Thieme Verlag: Stuttgart, 1965, issue V1/3, pp 24-32.
40. R. K. Griffith, R. A. DiPetro, Synthesis 1983, 576.
41. P. Dziuron, W. Schunack, Arch. Pharm. (Weinheim) 1973, 306, 347-350.
42. H. Stark, K. Purand, A. Hüls, X. Ligneau, M. Garbarg, J.-C. Schwartz, W. Schunack, Eur. J. Pharm. Sci. 1994, 2, 106.
43. C. Sellier, A. Buschauer, S. Elz, W. Schunack, Liebigs Ann. Chem. 1992, 317-323.
44. C. Sellier, PhD thesis, Freie Universität Berlin, Germany, 1991.
45. N. N. Janssen, J. Chim. Data Sheet No. 234.
46. P. Sieber, B. Riniker, Tetrahedron Lett. 1987, 28, 6031-6034.
47. C. R. Ganellin, A. Fkyerat, S. K. Hosseini, Y. S. Khalaf, A. Piripitsi, W. Tertiuk, J.-M. Arrang, M. Garbarg, X. Ligneau, J.-C. Schwartz, J. Pharm. Belg. 1995, 50, 179-187.
48. X. Ligneau, M. Garbarg, M. L. Vizuete, J. Diaz, K. Purand, H. Stark, W. Schunack, J.-C. Schwartz, J. Pharmacol. Ther. 1994, 271, 452-459.
49. E. Schlicker, H. Pertz, H. Bitschnau, K. Purand, M. Kathmann, S. Elz, W. Schunack, Inflamm. Res. 1995, 44, 296-300.
50. K. Onodera, S. Miyazaki, M. Imaizumi, H. Stark, W. Schunack, Naunyn Schmiedeberg's Arch. Pharmacol., in press.
51. J.-M. Arrang, M. Garbarg, J.-C. Lancelot, J.-M. Lecomte, H. Pollard, M. Robba, W. Schunack, J. C. Schwartz, Nature (London) 1987, 327, 117-123.
52. A. Hüls, K. Purand, H. Stark, X. Ligneau, M. Garbarg, J.-C. Schwartz, W. Schunack, Eur. J. Pharm. Sci. 1994, 2, 139.